Insulet price target lowered to $213 from $218 at Raymond James

Raymond James lowered the firm’s price target on Insulet to $213 from $218 and keeps an Outperform rating on the shares. Insulet’s revenue beat by 5% and profitability handily exceeded consensus estimates, as uptake of OP5 in Europe triggered an earlier-than-expected inflection in international growth, and this momentum should continue as OP5 is rolled out in new geographies, the analyst tells investors in a research note. Insulet remains one of the fastest growers in Med Tech, Raymond James argues.